Hi [[ session.user.profile.firstName ]]

Life Sciences

  • No More LC:  Microextraction Coupled with Direct MS Analysis
    No More LC: Microextraction Coupled with Direct MS Analysis Olga Shimelis, Principal R&D Scientist and R&D Supervisor, Merck KGaA, Darmstadt, Germany Recorded: Nov 16 2017 53 mins
    Mass spectrometry (MS) is an accepted research tool for both academic and industrial laboratories. As MS continues to gain ground in clinical and industrial testing, the requirements for high throughput, high sensitivity and high accuracy analyses put more emphasis on sample preparation. Solid Phase Microextraction (SPME) is well suited for this purpose as it requires minimal sample, provides pre-concentration of analytes, and allows for quantitative determinations.
    This webinar will focus on the use of microextraction devices for direct MS analysis for applications that do not require chromatographic separation. Such analysis often results in very high throughput and more immediate results in comparison to traditional methods. Several Direct MS interfaces will be reviewed. The relevant overview of the literature as applied to the direct MS analysis of microextracted samples will be presented. The presentation also will discuss in more detail the coupling of Direct Analysis Real Time (DART) with a new type of solid phase microextraction devices (known as BioSPME).
  • Can the New generation of perfusion technology compete or replace the convention
    Can the New generation of perfusion technology compete or replace the convention Ankur Bhatnagar & John Bonham-Carter Recorded: Nov 15 2017 76 mins
    Recently, there has been a renewed interest in the field of continuous processing. Some key factors driving this interest are – availability of better cell retention devices, improved cell lines and culture medium capable of supporting high cell densities.

    These factors have contributed mainly in reducing the batch duration for making the required quantity of product, thus reducing the medium requirement and chances of batch failures significantly. With the continuous processing being considered as ‘back-in-the-game’, the question remains: Can the current perfusion technology compete or replace the conventional and widely preferred fed-batch technology?

    Two cases are discussed to compare the performance features of fed-batch and perfusion processes. In both the cases, the product output from perfusion process is significantly higher (2 to 5 folds) than that from fed-batch, due to combination of factors like higher cell density, higher cell specific productivity, lower accumulation of toxic metabolites etc. These cases demonstrate the potential of perfusion process in significantly increasing the product output. However, there are certain challenges and points to be considered before a company decides to switch to a perfusion platform. Some of these are highlighted in the article.
  • iPSCs: The Future of Disease Research
    iPSCs: The Future of Disease Research Dr. Sharon Bahia, Product and Distributor Manager, The European Collection of Authenticated Cell Cultures (ECACC) Recorded: Nov 9 2017 36 mins
    The development of human iPSC technology offers researchers the ability to more accurately generate physiologically relevant models of disease and normal tissues in the laboratory. Advances in iPSC generation have allowed many laboratories to make their own cell lines; however, researchers rarely have the resources needed to establish stocks, undertake quality control and share their own de novo iPSC cell lines with other laboratories. A pre-existing and established iPSC collection therefore allows iPSC researchers to obtain “off the shelf” access to a large, robust and reliable supply of iPS cell lines that represent diverse donor to donor variability and which include disease status normal controls and gene edited cell lines. iPSCs from ECACC are standardised and quality controlled and have the benefit of coming from a trusted and internationally recognised collection with worldwide distribution.
  • Scopus Data for Ranking Organizations
    Scopus Data for Ranking Organizations M'hamed el Aisati, VP Funding, Content & Analytics Recorded: Nov 9 2017 59 mins
    Over the past 10 years, Scopus has emerged as the partner of choice in the fast-developing field of rankings. Join us for a discussion on the importance of A&I data to ranking organizations, and why they choose Scopus.
  • Single-Use & Stainless Steel BioReactors: Quality Factors for Consideration
    Single-Use & Stainless Steel BioReactors: Quality Factors for Consideration Dr Trevor Deeks, Principal and Consultant of Deeks Pharmaceutical Consulting Services, LLC Recorded: Nov 8 2017 76 mins
    Single-use (SU) systems are now in common use in pharmaceutical bioprocessing, as well as in other related technologies such as the manufacture of diagnostics and other biological products, and their popularity is increasing. Some types of SU systems have been in use for many decades now. The earliest SU systems being disposable filter cartridges that do not require a stainless steel (SS) filter housing. This present article seeks to focus in particular on SU bioreactors for cell culture and bacterial fermentation for the purpose of producing therapeutic proteins, monoclonal antibodies and vaccines. SU bioreactors are of particular value in early phase (Clinical Phases 1 and 2) GMP manufacturing. In some cases their use has now stretched through into commercial processing, albeit that the scale of operation is currently limited and in general the largest commercially available SU bioreactors are around 2000L working volume (WV). However, the small footprint that they require, and the reduction in investment needed for support services and utilities, means that the scale limitations can be overcome to a significant degree by having multiple SU bioreactors operating in parallel within a facility. The harvest from multiple bioreactors can be pooled for downstream processing, or each harvest can be processed as a separate batch, based upon considerations of the risks versus the economies of pooling.
  • Improving outcomes through industry partnership - the Cancer Vanguard learnings
    Improving outcomes through industry partnership - the Cancer Vanguard learnings Paul Tunnah(moderator)Steve Jowett(QuintilesIMS)Rob Duncombe(Christie NHS Foundation Trust)Stuart Hill(Merck)Mike Ringe(ABPI) Recorded: Nov 6 2017 68 mins
    The Cancer Vanguard is a bold initiative setup to take leadership in the delivery of the National Cancer Strategy – Achieving World-Class Cancer Outcomes published in 2015 with a key aim of designing and implementing new and increasingly patient centric models of care in Cancer that can benefit and be adopted by the wider national cancer system.
    In summer 2016 the Cancer Vanguard medicines optimisation team launched the ‘Pharma Challenge’ as an opportunity for the pharma and life sciences industry to identify innovative ways in which it could work in partnership with the NHS to improve the effective use of NHS resources, enhance the NHS’ understanding of the patient experience and make medicines optimisation part of routine practice. Four projects were taken forward including a partnership between the Cancer Vanguard, QuintilesIMS, Merck and uMotif,
    This unique example of partnership working across the health system is focussed on the service at large, not just the pill, and uses leading edge data analytics to analyse, benchmark and visualise the current state of the cancer pathways within the Cancer Vanguard Trusts. Furthermore it encompasses multiple aspects of the service provision ranging from patient outcomes and experiences, the flow of treatment and the usage of medicine in order to inform an evidence based and patient centric approach to service redesign and resource optimisation.
  • OncoCilAir™: A 3D human in vitro model for lung cancer research
    OncoCilAir™: A 3D human in vitro model for lung cancer research Samuel Constant, PhD, Co-founder, CEO Recorded: Nov 2 2017 38 mins
    In this special webinar, our guest presenter Samuel Constant Ph.D., Co-founder, CEO for OncoTheis will review:

    - Novel in vitro tests for modelling lung cancer
    - A model that allows long term monitoring of toxicity or efficacy on respiratory tract
    - How OncoCilAir™ is a 3D human airway epithelium with tumors reconstituted in vitro

    With more than 1 million deaths worldwide per year, lung cancer remains an area of unmet needs. Realistic human 3D models are required to improve preclinical predictivity. To that end, OncoTheis has engineered a novel in vitro lung cancer model, OncoCilAir™, which combines a functional reconstituted human airway epithelium, human lung fibroblasts and lung adenocarcinoma cell lines. Because of its unique lifespan (>3 month) and its dual composition (healthy and cancerous human tissues), OncoCilAir™ allows for the concurrent testing of the efficacy of drug candidates against malignant cells and their non-toxicity against healthy tissues. Accordingly, a first proof of concept study performed on a panel of anti-cancer drugs including the investigational drugs selumetinib and Mekinist® demonstrated that OncoCilAir™ carrying the KRASG12S mutation showed responsiveness in agreement with first clinical reported results, validating this unique tissue model as a predictive tool for anticancer drug efficacy evaluation. OncoTheis has now extended the model to EGFR mutations. Results showed that OncoCilAir™ EGFRdel19 is sensitive to Tarceva® and Iressa® treatments and provides a useful model to decipher in vitro mechanisms of resistance.
  • Characterisation of Host-Cell Proteins using Mass Spectrometry Enables Effective
    Characterisation of Host-Cell Proteins using Mass Spectrometry Enables Effective Dr Li Zang, Dr Chongfeng Xu and Dr Stephen Tate Recorded: Oct 31 2017 60 mins
    Common mammalian cell lines used for biopharmaceutical production include Chinese Hamster Ovary (CHO), NS0 and Human Embryonic Kidney (HEK) cells. Each of these cell lines has been found with over 20,000 genes coded in their genome, which can result in over 10,000 proteins expressed at the same time in these cells. These proteins can be secreted from the living host cells or released to the cell culture supernatant upon lysis of the host cells during the cell culture. Biopharmaceuticals produced using these cell lines can be co-purified with a subset of the host-cell proteins (HCPs) in the cell culture supernatant.

    These co-purified HCPs are considered process-related impurities for biopharmaceuticals. The HCPs can cause potential safety risks by introducing anti-HCP response in the patients. Depending on the biological functions of the residual HCPs, other potential impacts reported include lowering the biopharmaceutical protein stability and affecting the efficacy of the biopharmaceutical protein by exacerbating the symptoms.
  • Machine Learning Analytics for Financial Services
    Machine Learning Analytics for Financial Services Rodrigo Fontecilla,Vice President and Global Lead for Analytics, Unisys & Maria Allen, Senior Director & Global Head, Unisys Recorded: Oct 25 2017 61 mins
    Unisys advises banks, non-bank lenders, insurers, and payments providers developing data management and artificial intelligence capabilities. This webinar will showcase client examples applying machine learning and predictive analytics to optimize consumer engagement, identify fraud and cyber security risks, and bring new capabilities to credit modeling.

    About the Speakers:
    Rodrigo Fontecilla is vice president and global lead for analytics for Unisys Federal Systems, where he leads all aspects of software development, system integration, mobile development, and data management focused on the federal government. Rod is responsible for providing leadership, coordination, and oversight on all IT solutions, emerging technologies, and IT services delivery to the federal government. He has more than 25 years of professional experience in the capture, design, development, implementation, and management of information management systems delivering mission-critical IT solutions and has an extensive background and expertise in cloud computing, mobile development, social media, enterprise architecture, data analytics, SOA-based solutions, and IT governance.

    Maria L. Allen is Senior Director and Global Head of Unisys' Financial Services Portfolio Solutions. In this role, Maria is responsible for building new products and services across all regions, platforms and channels ensuring that solutions and services are delivered in a way that enable our clients to meet their strategic goals and objectives.

    For more information on our Advanced Analytics offerings contact us at advancedanalytics@unisys.com and visit http://www.unisys.com/analytics
  • Automation of the in vitro micronucleus assay using imaging flow cytometry
    Automation of the in vitro micronucleus assay using imaging flow cytometry Matthew. A Rodrigues, PhD., Research Scientist with Amnis-Merck KGaA, Darmstadt, Germany Recorded: Oct 24 2017 57 mins
    The in vitro micronucleus assay is one of the most widely used tests to quantify genotoxicity and cytotoxicity, especially as a screening tool in the development of chemicals and pharmaceuticals. Micronuclei (MN) are formed from whole chromosomes or chromosome fragments that lag behind during the metaphase-anaphase transition and are excluded from the main nucleus following division. MN form into small, rounded bodies surrounded by their own nuclear envelope and represent chromosomal mutations that can be used as an endpoint in genotoxicity testing. Typically performed by manual microscopy, the MN assay is laborious and can be subject to scorer bias. To overcome this, automated microscopy and conventional flow cytometry methods have been developed. However, these methods suffer from several limitations such as the requirement to create high quality slides in the case of microscopy and the lack of visual confirmation of MN in the case of flow cytometry. The ImageStream®X (ISX) imaging flow cytometer has the potential to overcome these limitations as it combines the speed, statistical robustness and rare event capture capability of conventional flow cytometry with high resolution fluorescent imagery.
    In this webinar, adaptation of the in vitro MN assay to an imaging flow cytometry-based method will be described. Using the ISX Mark II imaging flow cytometer, images of micronucleated mono- and binucleated cells as well as polynucleated cells can be captured at a high flow rate and automatically identified and scored in the Image Data Exploration and Analysis Software (IDEAS®) that accompanies the ISX. A data analysis template created specifically for this application allows for the determination of both genotoxicity and cytotoxicity following treatment with known clastogens and aneugens. This work is the first demonstration of fully automated method for performing the in vitro MN assay on an imaging flow cytometry platform.
  • Analytics 101 Part 2: Data Exploration & Predictive Modeling
    Analytics 101 Part 2: Data Exploration & Predictive Modeling Molly Jones, SAS Systems Engineer & Jen Lampert, SAS Solutions Architect Recorded: Oct 19 2017 55 mins
    In this webinar, we dive deeper into analytics and talk about the advantages of data exploration and predictive modeling. We’ll also show attendees how to fine-tune the accuracy and precision of those analytic models so you can make critical decisions with confidence.
  • The Truth about Doctors
    The Truth about Doctors Dominic Tyer Recorded: Oct 19 2017 65 mins
    McCann Health partnered with McCann Truth Central, the global intelligence unit of McCann Worldgroup, to conduct vital research.

    On the 19th October, McCann Health in association with PMGroup, will look at the truth they uncover about health.

    ‘The Truth about Doctors’ the first study in the series, aims to get to the heart of the human under the white coat to better understand what motivates doctors and how we can improve the way we communicate to them.
  • Recent developments in RAFT agents
    Recent developments in RAFT agents Dr. James Gardiner-Senior Research Scientist, Dr. Melissa Skidmore-Senior Research Scientist, Dr. Graeme Moad (CSIRO) Recorded: Oct 11 2017 41 mins
    This webinar will provide an overview of recent advances in RAFT agents (900150, 900157 and 900158). New dithiocarbamate RAFT agents are extremely versatile, RAFT agents with wide-spread monomer applicability. The RAFT agents have the distinct advantage of low odour levels and in addition to this and the derived polymers do not develop odour on storage as no low molar mass thiols are generated. In most cases they are an appropriate replacement for trithiocarbonate RAFT agents. The new RAFT agents have the ability to control polymerization of both MAMs (more activated monomers) and LAMs (less activated monomers) and have been shown to be suitable for the synthesis of poly(MAM)-block-poly(LAM), specifically poly(DMA)-blockpoly(VAc).
  • The Future of Pharmaceutical Manufacturing: Flexibility and Sustainability throu
    The Future of Pharmaceutical Manufacturing: Flexibility and Sustainability throu Daniel O. Blackwood & Jeffrey Moriarty of Pfizer, Inc. Recorded: Oct 10 2017 68 mins
    Following a decade (or more) of concerted effort by industry, regulator, and academic groups, recent technology investments are now beginning to shape how medicines are being developed and manufactured for the global marketplace. While significant focus has highlighted the emergence of continuous manufacturing processes, three additional trends have also influenced and served as underlying drivers for these technology investments. First, the emergence of scientific advances in targeted biology has created high-value personalized medicines with smaller manufacturing volumes (doses/annum). Second, new regulatory pathways, such as the FDA’s Breakthrough Therapy designation, have accelerated the development and commercialization timelines for these new medicines. Finally, manufacturing localization has extended supply chain networks to serve globally-distributed patient populations throughout the world. Together, these drivers have served to shape the future of pharmaceutical development, manufacturing, and distribution of a variety of different dosage forms. The increasing need for product development speed and commercial supply flexibility through small-footprint, modular equipment trains will be highlighted within this paper, using an immediate-release solid oral dosage form example.
  • Proving the Strategic Value of Patients
    Proving the Strategic Value of Patients Dominic Tyer Recorded: Oct 10 2017 48 mins
    Patient insights aren’t just a ‘nice to have’: they are essential to understand the space where Pharma’s drugs ‘live’.

    On the 10th October, Cello Health Insight in association with PMGroup, will look at the value of three areas of patient research that provide that ‘must have’ understanding: mapping the patient pathway, patient motivation, and the dialogue between patient and HCP.
  • Innovations in Multivariate Hematology Analysis
    Innovations in Multivariate Hematology Analysis Gert-Jan van de Geijn, Ph.D. Recorded: Oct 5 2017 51 mins
    In this on-demand webinar, Dr. Gert-Jan van de Geijn, renowned hematology expert, researcher and industry leader, discusses new chronic obstructive pulmonary disease (COPD) test parameters that better discriminate between bacterial and nonbacterial acute exacerbation. Dr. van de Geijn shares how neutro/lympho ratios and basophils (measured by flow) combined with current C-reactive protein (CRP) tests enable more accurate bacterial detection in COPD patients.

    After viewing this webinar, you will be able to:

    - Assess options based on the limitations of current differentiation tests (e.g., sputum culture and CRP)
    - Apply multivariate analysis results from hematology and flow cytometry technologies to increase specificity
    - Combine tests to improve prediction of bacterial exacerbation in COPD patients to help reduce antibiotics resistance

    For more insight, watch a recorded Q&A session that followed the live webinar.

    P.A.C.E. credit is available for your participation.*

    Gert-Jan van de Geijn, Ph.D., has nearly 20 years of experience in hematology and laboratory medicine. He is a specialist in multiple technologies related to cellular analysis, including both flow cytometry and molecular biological techniques. He has published and contributed to more than 30 research articles. Currently, Dr. van de Geijn is a research coordinator for the Department of Clinical Chemistry at Franciscus Gasthius Hospital, Rotterdam, the Netherlands.

    *Beckman Coulter, Inc. is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E.® Program. These credits are recognized by the State of California. At this time, we cannot issue continuing education credits for those who provide healthcare (or work for an institution that provides healthcare) in Massachusetts or Vermont.
  • Modeling NAFLD and TGFβ-induced Fibrosis in 3D Bioprinted Human Liver Tissue
    Modeling NAFLD and TGFβ-induced Fibrosis in 3D Bioprinted Human Liver Tissue Jeff Irelan, Ph.D. Recorded: Oct 5 2017 52 mins
    We hope you join us for this special webinar. Jeff Irelan, Director of Scientific Applications for Organovo will be our guest presenter.

    Nonalcoholic fatty liver disease (NAFLD) is the most common liver disorder with an estimated prevalence of over 25% worldwide and is projected to become the leading indication for liver transplant by 2025. Despite decades of research focused on NAFLD, an effective treatment has yet to be approved. This is due in part to the reliance on cell culture and animal models that present challenges in translation due to limited functional longevity and species differences, respectively.

    ExVive™ 3D Bioprinted Human Liver Tissue, a clinically-translatable in vitro model, is ideal for studying the effects of drugs on liver disease progression, regression, and the mechanisms involved. Here, we present results showing a nutrient overload induction of liver disease and TGFβ-induced fibrosis in ExVive™ Human Liver Tissue. A variety of disease-relevant phenotypes including steatosis, inflammation, and fibrosis can be demonstrated in the model:
    •Nutrient overload leads to the accumulation of lipid droplets in hepatocytes.
    •Incorporation of Kupffer cells and stimulation induces inflammatory cytokine release.
    •Chronic exposure to nutrient overload leads to stellate cell activation and fibrosis.
    •Chronic exposure to chemical inducers of fibrosis or TGFβ stimulation leads to stellate cell activation and fibrosis.
    •A TGFβR1 kinase inhibitor effectively blocks TGFβ-induced fibrosis.

    Presenter Bio:
    Jeff Irelan holds a Ph.D. in molecular biology from the University of Oregon. As Director of Scientific Applications, Jeff interfaces with Organovo’s customers and R&D team to implement and expand the company’s portfolio of service offerings utilizing bioprinted tissue models.
  • Seus clientes confiam na segurança da sua empresa, produtos e serviços?
    Seus clientes confiam na segurança da sua empresa, produtos e serviços? Leonardo Carissimi, Especialista em Segurança e Diretor de Soluções de Cybersecurity para América Latina da Unisys Recorded: Oct 5 2017 61 mins
    Saiba mais sobre as preocupações dos seus consumidores!

    O Unisys Security Index mede as preocupações dos consumidores em questões relacionadas à segurança nacional, pessoal, financeira e da Internet. O Unisys Security Index mostrou um aumento de 20% na preocupação de segurança geral em 2017. Saiba mais neste webinar onde iremos apresentar os detalhes do estudo e falar sobre como lidar com ameaças cibernéticas, o que os consumidores pensam sobre Internet das Coisas, e como aumentar a confiança de seus consumidores enquanto sua empresa avança na Transformação Digital.

    Leonardo Carissimi, Especialista em Segurança e Diretor de Soluções de Cybersecurity para América Latina da Unisys. Possui mais de 20 anos de experiência no setor de segurança. Na Unisys, ajuda a construir um mundo mais seguro, ao mesmo tempo em que transforma o setor de segurança com uma inovadora abordagem de microssegmentação, bem como a arquitetura de segurança adaptativa e a inteligência de ameaças cibernéticas.
  • ¿Sus clientes confían en la seguridad de su compañía, productos y servicios?
    ¿Sus clientes confían en la seguridad de su compañía, productos y servicios? Leonardo Carissimi, Experto en Seguridad y Director de Soluciones de Seguridad en América Latina de Unisys Recorded: Oct 3 2017 61 mins
    ¡Conozca las preocupaciones de sus clientes y actúe!

    El Unisys Security Index mide las preocupaciones de los consumidores en problemas relacionados a la seguridad nacional, personal, financiera y en Internet. El Índice Global de Seguridad mostró en 2017 un aumento de 20% en la preocupación general de seguridad. Aprenda más en este webinar sobre los detalles del estudio, cómo hacer frente a ciber amenazas, qué opinan los consumidores sobre el Internet of Things, y gánese la confianza de sus consumidores mientras continúa su proceso de Transformación Digital.

    Leonardo Carissimi, Experto en Seguridad y Director de Soluciones de Seguridad en América Latina de Unisys. Cuenta con más de 20 años de experiencia en la industria de seguridad. En Unisys, ayuda a construir un mundo más seguro mientras transforma la industria de seguridad con el innovador enfoque de micro-segmentación, así como con la Arquitectura de Seguridad Adaptativa y la Inteligencia de Ciber-Amenazas.
  • All About Scopus Content
    All About Scopus Content Dr. Wim Meester, Director of Product Management, Scopus Content Recorded: Sep 28 2017 45 mins
    Scopus has recently added over 195 million more cited references dating back to 1970 to complement the database's existing records that date back 1788 and further increase the depth of content.
    Added cited references mean:
    •more extensive bibliometric and historic trend analysis
    •more complete author profiles
    •improved h-index measures for authors who began publishing prior to 1996

    Learn more about the depth of Scopus content along with more insights into our content policies, selection criteria and data quality.
  • New Technologies for Cellular Research: 3-Dimensional Cell Culture and Screening
    New Technologies for Cellular Research: 3-Dimensional Cell Culture and Screening Richard M. Eglen, Ph.D Recorded: Sep 22 2017 54 mins
    It is now recognized that target and compound identification, as well as validation, are better conducted using cells with physiologically relevant phenotypes and genotypes. This assertion has accelerated the adoption of primary cells, stem cells, or patient-specific cells in cellular research, in general; and drug discovery, in particular.

    Technological improvements in three-dimensional (3D) cell culture technology, as a means to better mimic in vivo physiology, have accelerated recently—not only in the areas of cancer and neurological research, but also for the assessment of compound metabolic and toxicological liabilities. Furthermore, 3D cell culture can provide novel approaches to the scale-up and manufacture of biologically based medicines, including those used in immuno-and stem cell-based therapies.

    In this presentation, the existing and future impact of 3D cell culture technology on fundamental research, and drug discovery and manufacture will be addressed, particularly in the context of using phenotypically relevant cells. Specifically, it will discuss the potential for spheroids, organoids, scaffolds, and hydrogels in cellular research and compound identification, screening, and development.

    Future directions will also be covered, including organs-on-chips, hydrostatic flow technologies, microfluidics, and 3D bioprinting. Some of these approaches will allow for real-time observation of cellular responsiveness to novel compounds and drugs … boldly taking the researcher into a fourth dimension of 3D cell culture!
  • Stable Isotope-Labeled Protein Internal Standards
    Stable Isotope-Labeled Protein Internal Standards James Walters, Ph.D. Recorded: Sep 20 2017 56 mins
    Mass spectrometry-based protein assays impart increased specificity and more rapid development times versus traditional methods, such as ELISA. Coupled with immunoaffinity enrichment, LC-MS/MS is becoming a powerful tool for the quantitation of proteins in plasma. Such methods typically rely on synthetic stable isotope labeled (SIL) peptide internal standards to correct for instrumental variability. For more accurate protein quantitation by LC-MS/MS, experimental variations throughout the entire sample preparation workflow, including protein fractionation, immunoaffinity enrichment, and enzymatic digestion, must be accounted for. An ideal way of improving assay reproducibility is to add a full-length stable isotope labeled recombinant protein, that is equivalent to the native target protein, to the sample at the initial stage of the assay workflow. We have developed a set of stable-isotope-labeled monoclonal antibodies expressed in CHO cells as well as SIL versions of several clinically-relevant human proteins expressed in E. coli, such as IGF1, and in mammalian HEK293 cells, such as Thyroglobulin (manufactured as a Certified Reference Material). We will present data to demonstrate that the use of full-length SIL proteins and antibodies as internal standards allows for more accurate and rapid quantitation of biotherapeutic antibodies and clinically-relevant human protein biomarkers in plasma by LC-MS/MS.
  • Enabling Next Generation Pharma Supply Chain: The Role of the Digital Platform
    Enabling Next Generation Pharma Supply Chain: The Role of the Digital Platform Silvia Piai, Senior Research Manager, IDC Health Insights & Stefanie Naujoks, Senior Research Manager, IDC Manufacturing Recorded: Sep 20 2017 51 mins
    Damage, counterfeit, theft, delays: these are some of the most pressing challenges that pharma supply chain executives are facing. Consequences are not limited to disruptions and to higher costs for manually managing exceptions, identify irregularities, and tracing products: there's also direct impact on patient safety, and customer satisfaction putting company reputation at risk.

    In this webinar IDC analysts will share its research findings and provide guidance to pharmaceutical executives that want to start harnessing the real value of third generation digital platform, and implement a consistent, efficient and future-ready approach to supply chain management.

    About the Speakers:
    Silvia Piai is Senior Research Manager within IDC Health Insights for Europe Middle East and Africa. She is responsible for analyzing key trends related to IT strategies and spending in European healthcare organizations, and global Public Health institutions. She advises healthcare organizations and ICT vendors on planning and implementing effective digital health transformation initiatives to drive business innovation. Silvia’s analysis offers in-depth coverage of the technologies that provide the most clinical value in terms of quality, cost, time, and agility and are transforming pre-care, point of care (POC), and post-care today.

    Stefanie Naujoks is Senior Research Manager within IDC Manufacturing Insights, where she leads a new global program on Manufacturing Business Ecosystems Strategies. Her research includes managing supply networks, selling into new business ecosystems and manufacturing B2B Commerce, enabling better ecosystem collaboration through industry collaborative clouds, as well as automation and transparency within business ecosystems. Stefanie has published numerous market studies in the fields of digital transformation, IoT, Industry 4.0, Product Lifecycle Management (PLM), Manufacturing Execution Systems (MES) and Supply Chain Management (SCM).
  • Pharma’s digital landscape: the evolution of multichannel strategy
    Pharma’s digital landscape: the evolution of multichannel strategy Paul Tunnah (Moderator) with Oksana Matviienko (Viseven), Bogdan Rakytskyi (Teva) and Chris Wade (Veeva Systems) Recorded: Sep 19 2017 72 mins
    Pharmaceutical marketers are increasingly native multichannel practitioners, but building an effective and efficient campaign is challenging.
    This is also because the digital landscape, and the number of options available is still rapidly evolving.
    What are the best ways to choose the right channels and the right content? And how can you plan to optimize operations further by cutting down on costs and approval times?
    This webinar brings together experts in digital marketing with case studies from a leading pharmaceutical company to keep you up to date with the latest technology and trends and provide practical advice on how to maximize your impact.
    Within one hour, you’ll discover how to optimize and streamline all content-related processes within a single platform: starting with concept development and ending with the final launch. What is more, you will find out how to reuse and repurpose your ready-made content cost-effectively, as well as save time while adapting and updating content through its whole lifecycle.
    •How to develop best practice and a winning multichannel strategy
    •Making sure your content supports face-to-face interactions
    •Transforming the commercial teams to deliver successful digital and multichannel projects
    •How to innovate in multichannel, and the potential of future integration solutions
  • Advances in Mass Spectrometry for the Analysis and Bioanalysis of Antibody-Drug
    Advances in Mass Spectrometry for the Analysis and Bioanalysis of Antibody-Drug Arnaud Delobel, PhD Recorded: Sep 12 2017 34 mins
    ADCs are complex compounds resulting from the coupling of cytotoxic small molecules to a monoclonal antibody. Their characterization as well as their bioanalysis (quantification in biological fluids) remains challenging. Mass spectrometry at different levels (intact, middle, peptide) can be a valuable tool, and can now be used in a regulated environment thanks to advances in both hardware and software.
  • UNLEARN. RELEARN. REIMAGINE. Smarter communications through behavioral science
    UNLEARN. RELEARN. REIMAGINE. Smarter communications through behavioral science Dr Paul Tunnah, David Hogben (Complete HealthVizion), Robert Poole (Complete HealthVizion), Bjarke Ebert (Lundbeck) Nov 22 2017 3:00 pm UTC 75 mins
    How can we create smarter, more effective communications for HCPs and patients? What can be done to challenge the status quo, apply a different mindset to communications, and deliver the best possible patient outcomes?

    In this webinar, we will discuss how multichannel strategy and behavioural science are natural partners in creating smarter, more meaningful, and more effective communications. The premise is simple: if we apply a behavioural mindset, we can determine where to focus our communications for the best effect, design the most appropriate multichannel strategy and content, and put the right metrics in place to measure success.
  • The evolution of pharma social media intelligence
    The evolution of pharma social media intelligence Paul Tunnah(Moderator); Professor Andrew Stephen (University of Oxford); Anurag Abinashi (IQVIA) Nov 23 2017 12:30 pm UTC 75 mins
    Is your company a fully mature user of intelligence from social media, or is it still not tapping into insights?

    As shown in the consumer world, social media can be a very rich source of insights into customers and markets, and can provide early signals of new trends. Exactly the same is true for patient and health care provider insights, especially when used with other more traditional data sets.
    But understanding how to engage, and how to extract the right data to get actionable insights – and all the while complying with regulations – isn’t so straightforward.

    Life sciences companies in particular, want to put this new data source in context with its already broad range of metrics. Achieving this calls for a step-by-step progression towards social media maturity.
    pharmaphorum is working in collaboration with experts from IQVIA and Professor Andrew Stephen of Oxford University to deliver a topical debate focussed on this field, intended to provide answers to some of the conundrums the industry faces.

    An expert panel will provide practical advice and real-life examples of how pharmaceutical companies can develop maturity in social media intelligence.

    Increase your understanding of how social media can easily be used to ultimately add value

    Learn the tricks - how, when and why marketers from other sectors use social media channels to their advantage

    Hear how leading pharma organisations have embraced social media and have seen real results
  • Improving commercial decisions with customer relationship network insights
    Improving commercial decisions with customer relationship network insights Megan Oh (Abbott), Leilani Latimer (Zephyr Health), Paul Tunnah (pharmaphorum) Nov 28 2017 7:00 pm UTC 75 mins
    Networks of influence are shifting the decision-making process for life sciences companies. It is no longer enough to simply view the profile of a HCP or HCO to understand their value to your organization.

    For life sciences organizations, there is currently a gap in information, understanding, and digital access to these critical customer networks and relationships.

    Relying solely on internal knowledge, field experience or purchased data provides an analog, one-dimensional view of these networks. This limits companies from fully understanding key influencers, referral pathways, speaker and authorship networks and more, which once uncovered can significantly influence customer outreach, messaging and engagement.

    In this webinar, we’ll discuss how companies who embrace a holistic data and network analytics approach to strategic planning and execution can achieve significant competitive advantage, improved customer engagement and faster market penetration.
  • The Future of Marketing in Life Sciences: Is your function fit for purpose?
    The Future of Marketing in Life Sciences: Is your function fit for purpose? Dominic Tyer Nov 30 2017 2:00 pm UTC 60 mins
    The healthcare landscape is rapidly changing as it responds to a multitude of well-known issues. Coupled with emerging digital technologies, these drivers are shaping the industry, moving it towards a more sophisticated, outcomes-driven model that demands a new approach. The new world emerging is one in which value is defined, created and evaluated in a very different way, with marketing playing a critical role.

    On 30 November, EY (a global leader in assurance, tax, transaction and advisory services) in association with PMGroup, will host a free webinar debating the future of marketing in Life Sciences. Is your function fit for purpose?
  • Characterization of sub-visible particles with Amnis imaging flow cytometry
    Characterization of sub-visible particles with Amnis imaging flow cytometry Christine Probst, Application Scientist - Merck KGaA, Darmstadt, Germany Nov 30 2017 4:00 pm UTC 75 mins
    Multi-spectral imaging flow cytometry (MIFC) is an established analytical method for cellular analysis, however has only recently been evaluated for characterization of sub-visible particles in therapeutic formulations despite numerous favorable attributes including:

    • Simultaneous collection of bright-field, side-scatter, and fluorescent imagery
    • Sensitive detection of particles 100 nm-100 μm
    • High image quality using 20X-60X magnification objectives
    • 100% sampling efficiency using hydrodynamic focusing
    • Small sample volume requirement (20 μL)
    • Linear concentration range up to 100 million/mL
    • Wide flow cell (250 μm) minimizes clogs

    Assorted case studies using MIFC for analysis of protein and vaccine formulations will be presented, with an emphasis on measurements and samples that pose challenges for current techniques- including detection of small and transparent particles, direct analysis of highly concentrated formulations, and fluorescence characterization of particle type, chemical composition, and heterogeneous interactions.
  • Driving positive change for patients through collaboration and education
    Driving positive change for patients through collaboration and education Jessica Bateman (UCF); Phyllis Greenberger (HealthyWomen); Steven Gregg (NAFC), Jenny Kite (Astellas US) Dec 4 2017 5:30 pm UTC 75 mins
    Change Together – www.changetogether.com – will be presenting a live webinar with leading figures from the patient advocacy community, who will debate how we can drive positive change for patients through collaboration and education. This will be helpful for all advocates, as we hear and learn from our expert panel how their organizations are bringing about change.

    The key topics our expert panel will be covering are:
    – The power of collaboration
    – Educating and communicating with physicians for better patient care
    – Using social media and paid search to extend online engagement and reach
    – Effecting health policy change at a federal and state level
  • SPME Applications in Food Analysis by means of a New Matrix Compatible Coating
    SPME Applications in Food Analysis by means of a New Matrix Compatible Coating Emanuela Gionfriddo, Ph.D.; Research Associate under Prof. Janusz Pawliszyn, University of Waterloo (ON, Canada) Dec 7 2017 2:30 pm UTC 75 mins
    The complexity and diversity of food matrices, and the need for clean extracts to be injected into analytical instrumentation may imply the use of tedious and time-consuming sample preparation strategies that often produce significant laboratory waste. The development of a new matrix-compatible solid phase microextraction (SPME) coating, namely PDMS/DVB/PDMS, bearing enhanced antifouling properties, enables the analysis of complex food matrices by direct immersion SPME, and helps to overcome issues related to extensive sample pre-treatment and instrumental contamination. This webinar will focus on recent advances made toward the analysis of contaminants in complex food samples by using the new matrix-compatible SPME coating, and will describe the optimization of important parameters to be considered when performing Direct Immersion SPME (DI-SPME).
  • USP : Methods for Moisture Determination and Karl Fisher Titration
    USP : Methods for Moisture Determination and Karl Fisher Titration Bruce Herzig, Sr. Application Scientist, Merck KGaA, Darmstadt, Germany Dec 7 2017 4:00 pm UTC 90 mins
    Many Pharmacopeia materials contain water as hydrates or in adsorbed form. Therefore the determination of the water content is important to maintaining compliance with the Pharmacopeia guidelines. Generally one of the three methods are given in the monographs, Method I (Titrimetric), Method II (Azeotropic), or Method III (Gravimetric). This poster will discuss the application of these methods to moisture determinations focusing on Karl Fischer techniques.
  • Rapid Fontana-Masson Staining
    Rapid Fontana-Masson Staining Vikas Palhan, PhD, Senior R&D Scientist, Emerging Biology - Genomics Dec 14 2017 3:00 pm UTC 75 mins
    In the continued effort to save you time and simplify your workflow, we’ve developed a Fontana-Masson Staining Kit with a protocol that is 30x faster than the standard protocol. In this webinar, the researcher who developed the kit explains how easy it is to use this new rapid microwave technique. If you need to stain melanin and argentaffin cells in tissue sections, take a few minutes to watch this webinar - and save yourself many more minutes in the future by using this kit.
  • Total Nitrogen Test Kits as an Alternative to TKN, Nitrate, and Nitrite Tests
    Total Nitrogen Test Kits as an Alternative to TKN, Nitrate, and Nitrite Tests Taylor Reynolds; Ed Askew Ph.D. Dec 14 2017 5:00 pm UTC 75 mins
    Currently the US EPA has not promulgated a method for the analysis of Total Nitrogen (TN). Most states that have TN regulations require permitee's to measure TN as the composite of TKN, Nitrate and Nitrite. This approach is costly, time consuming, and also susceptible to variability based on the methods used for the individual analytes Merck, KGaA, Darmstadt, Germany is excited to announce the introduction of a Total Nitrogen Test Method consisting of a single spectrophotometric test kit. The method has been evaluated in a multilab study and this webinar will present the results of that study as well as an overview of the savings made possible by utilizing this new method for testing Total Nitrogen.
  • Towards Real Time Release testing: Dissolution prediction of tablets made using
    Towards Real Time Release testing: Dissolution prediction of tablets made using Dr Erik Skibsted Jan 10 2018 3:00 pm UTC 75 mins
    After 50 years of near-stagnation, pharmaceutical manufacturing is experiencing unprecedented scientific and technological innovation. There is a paradigm shift from testing product quality using lengthy off-line (and after-the-fact) assays to quality being tested during the process using online/ at-line measurements. This ability to evaluate and ensure quality of final product based on process data, geared towards making batch release decisions, is known as real time release testing (RTRt). A case study for predicting dissolution profiles of tablets made using CDC is presented. The methodology enables real-time release testing. Four different parameters were varied in the CDC line; API concentration, blender speed, feed frame speed, and compaction force, and their effect on tablet dissolution was investigated. Model dependent and model independent approaches were used to extract information from dissolution profiles. Multivariate regression was built between the information obtained from the NIR as the predictor variables and the dissolution profile parameters as the response. This enabled prediction of dissolution profiles for test samples made using CDC. Alternative RTRt approaches towards dissolution prediction will also be discussed.
  • Gene and Cell Therapy – An Overview of the Current and Changing Regulatory
    Gene and Cell Therapy – An Overview of the Current and Changing Regulatory Mark D. Johnson, MS; Scott E. Boley, PhD, DABT Jan 12 2018 3:00 pm UTC 90 mins
    Gene and Cell Therapy – An Overview of the Current and Changing Regulatory Requirements and Study Design for Nonclinical Safety Evaluation

    Nonclinical development of gene and cell therapies has been ongoing for more than three decades, and has been increasing in recent years. In the early days of these efforts, these therapies shared the fate of many novel experimental medicine approaches with progress impeded by severe side effects in treated patients or a failure to demonstrate efficacy in the target patient population. Research over the past decade has resulted in the development of highly sophisticated gene transfer tools with improved safety and therapeutic efficacy. As these tools have been developed, regulatory agencies worldwide have adapted new review processes and developed a wide range of guidance documents to aide researchers in designing rigorous nonclinical studies to ensure the safety, biodistribution and potential benefit of these advanced therapeutics. This presentation will provide an overview of the regulatory guidelines, provide some key considerations in the nonclinical development and testing of cellular and gene therapies, and detail several case studies of these therapeutics.
  • Enabling comprehensive data analytics and process monitoring in Biomanufacturing
    Enabling comprehensive data analytics and process monitoring in Biomanufacturing Robert Dimitri, Hugo Guerra and Gloria Gadea-Lopez, Ph. D Jan 17 2018 3:00 pm UTC 75 mins
    Technical teams rely on the availability of meaningful data and effective tools to perform process monitoring, to conduct root cause analysis and investigations and, most of all, to obtain new insights into their operations. In this article, the authors discuss the implementation and management of a comprehensive system for data analytics at Shire –Lexington, MA site, the lessons learned, and practical advice towards the successful deployment of these key applications.
  • Disposables – Suitability and Process Economy In Biopharmaceutical Manufacturing
    Disposables – Suitability and Process Economy In Biopharmaceutical Manufacturing Dr Joachim Walter Jan 24 2018 3:00 pm UTC 75 mins
    Since the introduction of disposables and gaining popularity of Single-use Technology (SUT) for biopharmaceutical manufacturing there is nevertheless an ongoing controversial discussion on the advantages and disadvantages versus a conventional stainless steel environment.

    In a “classical” facility design any validation cost effort can easily be distributed to a considerable number of production runs thus contributing only to a non-decisive amount to the overall production costs. The scale for such plant is nearly unlimited as is the scale of operation. The “flexible” approach using disposables and single-use equipment offers significant advantages regarding changeover work and time thus a high throughput of different processes will definitely take profit as any cleaning and related validation and costly analytics doesn’t apply to a larger extent.

    Despite the potential benefits loudly advertised by the respective industry, these potential advantages derived from single-use equipment and disposables can be significantly diminished by lack of detailed process cost analysis, missing economic analysis and cost comparison between conventional and SU technologies as well as underestimating the cost of long term dependency on consumables. Due to missing appropriate standards, there is a widely non-compatibility between the equipment and consumables of the various suppliers, resulting in a strong dependence on the consumables of a single supplier once a single-use equipment has been purchased, curiously leaving some customers with surprise that they hardly have any room for price negotiations on the required consumables.
    This paper’s focus is on the very different arguments for the application of SU equipment and consumables, including advantages and limitations of SUT, understanding improvement of process robustness, contribution to lean production as well as environmental impact of disposables.
  • Do Extractable Protocols Truly Help- An End User Perspective
    Do Extractable Protocols Truly Help- An End User Perspective Ekta Mahajan, Genentech/Roche Feb 5 2018 3:00 pm UTC 75 mins
    Single Use technology is being used more each year in the biotechnology industry. However, extractables and their potential impact on product and patients continue to be one of the biggest challenges. The challenge is augmented by the lack of standardized methodology for suppliers to execute extractable studies that meets end user requirements. The end users are responsible and required by law to assess the impact of extractables and leachables on overall Product Quality and Safety. Due to lack of a standard, customized data had to be generated for/by each end users. This resulted in long lead times, higher costs and inefficient utilization of resources. Typically, the data generation and qualification of single use component can take up to a year, which can impact implementation of single use. BioPhorum Operations Group (BPOG) developed a standardized protocol9 for generating extractable data that would meet user requirements and simplify/reduce implementation time within industry. A standardized protocol gives confidence to suppliers that testing performed by them would meet end user requirements and enable faster implementation. Some suppliers shared the BPOG vision and proactively tested their single use components using BPOG protocol, which has helped expedite the use of their products.
  • Efficient execution of biologics manufacturing – The role of Finite Scheduling
    Efficient execution of biologics manufacturing – The role of Finite Scheduling Gloria Gadea-Lopez, Ph.D., John Maguire and Gerry Glennon Feb 14 2018 3:00 pm UTC 75 mins
    The success of manufacturing relies on the availability of all the resources –personnel, materials, equipment, work instructions - , orchestrated in such a way that the operations proceed in an efficient and predictable manner. This article describes the implementation of a finite scheduling system for biologics production, the foundational work required prior to project launch, lessons learned, and benefits achieved from this deployment.
  • Process analytical Technology for Upstream Bioprocessing
    Process analytical Technology for Upstream Bioprocessing Erica Fratz-Berilla & LCDR Agarabi Mar 5 2018 3:00 pm UTC 75 mins
    In commercial cell culture bioprocessing, consistent high quality protein is a fundamental goal that is typically accomplished during development through product and process engineering of bioreactor parameters. The FDA’s Center for Drug Evaluation and Research (CDER)’s Office of Biotechnology Products’ upstream bioprocessing laboratory, a part of the Office of Pharmaceutical Quality’s Center of Excellence (COE) in Manufacturing Science and Innovation, studies Process Analytical Technology (PAT) for upstream bioprocessing, focusing on the production of monoclonal antibodies. These capabilities are being leveraged to study continuous bioreactor cell culture production and compatible PAT tools. Case studies are presented that illustrate collaborative laboratory research being conducted on PAT tools for upstream bioprocessing to support regulatory decision making.
  • Application of Multivariate Data Analysis for Process Diagnostic and Root Cause
    Application of Multivariate Data Analysis for Process Diagnostic and Root Cause Ramila Peiris, Ph.D., Manager, Process Modelling and Process Analytical Technology, Sanofi Pasteur Mar 7 2018 3:00 pm UTC 75 mins
    The utilization of Multivariate Data Analysis (MVDA) techniques at Sanofi Pasteur, Toronto site has demonstrated innovative capabilities for improved process understanding, control and diagnostics. Examples from several successful and high impact applications will be presented. These examples cover the application of MVDA techniques in multivariate process control, root cause investigations and process analytical technology (PAT). The areas of application include fermentation, downstream purification and product formulation stages.
  • Project and Portfolio Management as a key tool to manage continuous improvement
    Project and Portfolio Management as a key tool to manage continuous improvement Gloria Gadea-Lopez, Ph.D.and Melvin Santos Mar 14 2018 2:00 pm UTC 75 mins
    Continuous improvement, risk mitigation and adherence to compliance rely on the successful execution of key initiatives aligned with an organization’s strategic imperatives. This article summarizes the Project and Portfolio initiatives at Shire’s Biologics manufacturing facility at Shire, Lexington, MA site. In addition to practical advice, the authors discuss the need for sound business processes, alignment with Finance and budget cycles, and play special attention to the importance of resource allocation and management.
  • SUS Leachable Testing: Leachable Study Design for Single-Use Components
    SUS Leachable Testing: Leachable Study Design for Single-Use Components Kathryn McGohan Mar 20 2018 2:00 pm UTC 75 mins
    The BPOG Leachables Working Group has recently published a Best Practice Guide for Leachables. The Best Practice Guide was developed to help Biopharmaceutical and Vaccines Manufacturers to develop science-based, robust, and efficient approaches to handling the risk of leachable compounds that is associated with increasing use of Single-Use Systems in manufacturing processes. The Best Practice Guide is composed of three parts: the risk assessment model, leachable study design, and analytical methods. This article provides insight into the application of the Best Practices for Leachables Study Design by end users and will include a case study to highlight the importance of the study design.
  • DSF and FTIR as methods for the identification and characterization
    DSF and FTIR as methods for the identification and characterization Marina Kirkitadze and Kristen Kalbfleisch Mar 21 2018 2:00 pm UTC 75 mins
    The focus of this presentation is the application of Fourier Transform Infrared Spectroscopy (FTIR) and Differential Scanning Fluorimetry (DSF) methods to characterize vaccine components and their stability. Additionally, FTIR can be applied for the identification of final vaccine products, and DSF can be used to distinguish different formulations of vaccine candidates. These methods, when used in conjuction, provide valuable information regarding characterization and stability in the final stages of vaccine manufacturing.
  • Applied Analytical Techniques to Monitor IsoAsp in Biologics Formulation Develop
    Applied Analytical Techniques to Monitor IsoAsp in Biologics Formulation Develop Dominick Gerald DeGrazio, Janssen Apr 10 2018 2:00 pm UTC 75 mins
    The development of a suitable biologic formulation occurs often before analytical methods are validated. Certain chemical modifications are critical to monitor during the development process as they may cause protein instability and reduce biologic efficacy. Aspartic acid isomerization is one such modification, but is arguably the most difficult to detect. Analytical tools to track IsoAsp are discussed that can aid in making formulation decisions before the availability of qualified methods.
  • Key components of a comprehensive program for the management of single use techn
    Key components of a comprehensive program for the management of single use techn Mark Maselli Apr 19 2018 2:00 pm UTC 75 mins
    As a result of the increased adoption of single-use technologies (SUTs) in biotech manufacturing, companies need to develop and implement programmatic approaches for the management of these systems under regulatory compliance. This webinar discusses the key aspects of such programs, with emphasis on collaboration with suppliers, cost management, as well as practical insights about the use of SUTs.